Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here

Amphastar is rated Buy with a $33 fair value implying roughly 81% upside. The firm expects mid- to high-single-digit revenue growth in 2026 driven by Baqsimi and new launches despite declining sales in legacy products. Operating margin is forecast to dip to ~22% in 2026 due to higher expenses, then recover to ~26% by 2030 as higher‑margin pipeline products ramp. The note is constructive on long-term upside but flags near-term margin pressure.

Analysis

The immediate competitive lever is commercial execution — how quickly Amphastar converts Baqsimi adoption into recurring channel demand while preventing legacy product declines from pulling overall realized price down. Nasal-device scale and third-party CMOs that supply nasal delivery components are implicit beneficiaries if Amphastar outsources ramp; conversely, distributors and GPOs gain negotiating leverage as legacy volumes fall, increasing the risk of steeper net price erosion than headline growth implies.

Near-term margin pressure is not just elevated SG&A for launches; working-capital and inventory phasing create a pronounced timing risk. If Amphastar pushes inventory into specialty pharmacies to hit 2026 top-line targets, Q4–Q1 comps could look artificially strong but set up a tougher 2027 recovery — watch days-sales-inventory and return rates over the next 3–6 quarters to distinguish genuine demand from channel stuffing.

Key catalysts and tail risks operate on different clocks: quarterly guidance and formulary wins move the stock in weeks–months, while pipeline-driven margin recovery is a multi-year story dependent on manufacturing yield and reimbursement wins. Regulatory repricing (payer pushback) or an unexpected generic entrant into legacy injectables are low-probability, high-impact downsides that would wipe out the mid-term margin thesis quickly.

Contrarian read: consensus appears to price a smooth ramp from launch into higher-margin mix; that’s optimistic. Execution slippage or slower formulary penetration would compress operating margin beyond current guidance and would disproportionately punish the equity given the valuation premium on the future pipeline. Monitor gross margin, DSO/DSI, and incremental marketing spend per incremental Baqsimi prescription as the quickest early-warning signals.

Key Decisions for Investors

• Core long (equity + hedge): Buy AMPH on weakness with a 12–18 month horizon. Size at 1–2% NAV, and buy a 12-month protective put (e.g., ~$15 strike) to cap downside to ~15–20% while retaining most upside to the fair-value target. R/R: asymmetric upside (~+70–90%) vs limited downside net of premium.
• Leveraged directional (options): Buy Jan 2027 LEAPS call (25–36 month) or a 12–18 month 30/45 call spread to finance cost. This captures the multi-year margin recovery while limiting capital; max loss = premium, upside ~3x+ if pipeline ramps per plan.
• Tactical pair (months): If evidence of channel stuffing appears (rising inventory days or abnormal distributor orders), switch to pair trade: trim AMPH exposure and rotate into a defensive healthcare distributor ETF or large-cap diversified pharma (sell AMPH delta via short dated calls to fund protection). This protects against a 3–6 month reversion event.
• Triggers & monitoring: Enter or add on a confirmed sequential improvement in gross margin and a fall in DSI/returns over two consecutive quarters, or on a clear set of formulary wins. Take profits or re-assess if SG&A/sales ratio stays elevated beyond two fiscal years or if material generic competition emerges.